Cost effectiveness of low-dose zidovudine therapy for asymptomatic patients with human immunodeficiency virus (HIV) infection

Annals of Internal Medicine

Volumn 114, Issue 9, 1991, Pages 798-802

  Schulman, Kevin A ^a,b   Lynn, Lorna A ^a,b   Glick, Henry A ^a,c   Eisenberg, John M ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG DOSE; ECONOMICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SURVIVAL;

AZT; CLINICAL APPROACH/SOURCE; COSTS AND BENEFITS; EMPIRICAL APPROACH; HEALTH CARE AND PUBLIC HEALTH; PROFESSIONAL PATIENT RELATIONSHIP; UNITED STATES;

ACQUIRED IMMUNODEFICIENCY SYNDROME; CD4-POSITIVE T-LYMPHOCYTES; COST-BENEFIT ANALYSIS; HIV INFECTIONS; HUMAN; LEUKOCYTE COUNT; LIFE EXPECTANCY; MODELS, STATISTICAL; PROBABILITY; SURVIVAL ANALYSIS; ZIDOVUDINE;

EID: 0025853367     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-114-9-798     Document Type: Article

References (22)

1. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. N Engl J Med. 1990;322:941-9.
2. Hilts PJ. Drug said to help AIDS cases with virus but no symptoms. New York Times. 1989 Aug 18:A-1,A-13.
3. Hilts PJ. Major changes for health system seen in wake of AIDS finding. New York Times. 1989 Aug 19:A-1,A-8.
4. [Anonymous]. A life-saving AIDS strategy [Editorial]. New York Times. 1989 Aug 20:E-22.
5. Weinstein M, Stason WB. Cost-effectiveness of interventions to prevent or treat coronary heart disease. Annu Rev Public Health. 1985;6:41-63.
6. Kinosian BP, Eisenberg JM. Cutting into cholesterol. Cost-effective alternatives for treating hypercholesterolemia. JAMA. 1988;259: 2249-54.
7. Hellinger FJ. Updated forecasts of the costs of medical care for persons with AIDS, 1989-93. Public Health Rep. 1990;105:1-12.
8. Scitovsky AA, Rice DP. Estimates of the direct and indirect costs of acquired immunodeficiency syndrome in the United States, 1985, 1986, and 1991. Public Health Rep. 1990;102:5-17.
9. College of American Pathologists. Manual for Laboratory Workload Recording Method. Skokie, Illinois: College of American Pathologists; 1982.
10. Goedert JJ, Kessler CM, Aledort LM, et al. A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia. N Engl J Med. 1989; 321:1141-8.
11. Lemp GF, Payne SF, Neal D, et al. Survival trends for patients with AIDS. JAMA. 1990;263:402-6.
12. Ward JW, Bush TJ, Perkins HA, et al. The natural history of transfusion-associated infection with human immunodeficiency virus: factors influencing the rate of progression to disease. N Engl J Med. 1989;321:947-52.
13. Fischl MA, Richman DD, Grieco MH, et al. Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. AZT Collaborative Working Group. JAMA. 1989;262:2405-10.
14. Centers for Disease Control. HIV/AIDS Surveillance Report. Atlanta, Georgia: Centers for Disease Control; October 1990:1-18.
15. National Center for Health Statistics. Annual summary of births, marriages, divorces, and deaths: United States, 1988. Monthly Vital Statistics Report. 1989;37:1-30.
16. Years of potential life lost before age 65 - United States, 1987 and 1988. MMWR. 1990;39:20-2.
17. Report of the Second Public Health Service AIDS Prevention and Control Conference. Public Health Rep. 1988;103(Suppl 1):35.
18. Backgrounder. ACTG 019 - Questions and answers. Bethesda, Maryland: National Institute of Allergy and Infectious Disease; 1989 Aug 17.
19. Cummings SR, Rubin SM, Oster G. The cost-effectiveness of counseling smokers to quit. JAMA. 1989;261:75-9.
20. Garner TI, Dardis R. Cost-effectiveness analysis of end-stage renal disease treatments. Med Care. 1987;25:25-34.
21. Eddy DM, Hasselblad V, McGivney W, Hendee W. The value of mammography screening in women under age 50 years. JAMA 1988;259:1512-9.
22. Winkenwerder W, Kessler AR, Stolec RM. Federal spending for illness caused by the human immunodeficiency virus. N Engl J Med. 1989;320:1598-603.